A phase I trial of CT900, a novel α-folate receptor-mediated thymidylate synthase inhibitor, with expansion cohorts in patients with high grade serous ovarian cancer

Overview of attention for article published in Clinical Cancer Research, August 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
Good Attention Score compared to outputs of the same age and source (79th percentile)

So far, Altmetric has seen 21 X posts from 16 X users, with an upper bound of 71,672 followers.

Our third featured paper is co-authored by Ionut-Gabriel Funingana, and Bristi Basu, from Medical Oncology at @CUH_NHS : https://t.co/X5AKF9cLmA #CUHAuthors

RT @CCR_AACR: Phase 1 Study: α-folate receptor-mediated thymidylate synthase inhibitor. https://t.co/dlohEvoDOH https://t.co/a4TLz3bVqu

Phase 1 Study: α-folate receptor-mediated thymidylate synthase inhibitor. https://t.co/dlohEvoDOH https://t.co/a4TLz3bVqu

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 17 additional X posts.